FLT3 inhibitors in acute myeloid leukemia

Table 3 Clinical trials of lestaurtinib for AML

Study agents	Other agents	Disease	Dose	No Pts	Response	Reference
Lestaurtinib	Chemotherapy	Untreated	60–80 mg twice daily	27	OR 60% in mutated FLT3 OR 23% in wild-type FLT3	[38]
Lestaurtinib		Relapsed Refractory	60 mg twice daily	14	OR 35%	[39]
Lestaurtinib	Chemotherapy	Relapsed	80 mg twice daily	224	CR/CRp 26%	[40]
Lestaurtinib	Chemotherapy	Untreated		500	5-year OS 46% 5-year RFS 40%	[41]

OS overall survival, RFS relapse-free survival, CR complete remission, CRp complete remission incomplete platelet recovery

ISSN: 1756-8722